Drug intelligence / Profile preview

AR168

Development stage: Preclinical
Lead developer: Y Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AR168 is a monoclonal antibody currently in the discovery phase of development by Y Biologics. It is being investigated for the treatment of autoimmune diseases. As of the current pipeline information, the specific biological target of AR168 remains undisclosed by the developer. The drug is part of Y Biologics' early-stage portfolio of antibody-based therapeutics, which utilizes their proprietary antibody library and engineering platforms to address unmet needs in immunology.

Beyond the preview

Go deeper on AR168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR168.

Explore the full profile